Gilead Sciences announced that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.
Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.
Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics.
Schrödinger and Bayer announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs.
Tyme Technologies and Eagle Pharmaceuticals have entered into a collaboration deal worth up to $40m restricted to the US for co-promoting the former’s lead compound SM-88 in advanced cancers.
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring.
Bicycle Therapeutics has joined hands with Cancer Research UK for the development of a new immune-oncology candidate.
GlycoMimetics and Apollomics announced an exclusive collaboration and license agreement for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.
Merck has joined hands with Japan’s Taiho Pharmaceutical and the UK’s Astex Pharmaceuticals in an oncology collaboration worth $2.5bn.
Leap Therapeutics has announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.